Carlos L. Arteaga

Carlos L. Arteaga

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Carlos L. Arteaga

UT Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 April 2020 in Cancer Cell
Verified
Journal Article
Closed access
AHAriella Hanker
Ariella Hanker
DSDhivya R. Sudhan
Dhivya R. Sudhan
CACarlos L. Arteaga
Carlos L. Arteaga

14 January 2016 in Annual Review of Medicine
Verified
Journal Article
Closed access
IMIngrid A. Mayer
Ingrid A. Mayer
CACarlos L. Arteaga
Carlos L. Arteaga
Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review. Expected final online publication date for the Annual Review of Medicine Volume 67 is January 14, 2016. Please see http://www.annualreviews.org/catalog/pubdates.aspx for revised estimates.

31 March 2014 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RJRinath Jeselsohn
Rinath Jeselsohn
RYRoman Yelensky
Roman Yelensky
GBGilles Buchwalter
Gilles Buchwalter
GFGarrett Frampton
Garrett Frampton
FMFunda Meric-Bernstam
Funda Meric-Bernstam
VMVincent A. Miller
Vincent A. Miller
Purpose: We undertook this study to determine the prevalence of estrogen receptor (ER) α (ESR1) mutations throughout the natural history of hormone-dependent breast cancer and to delineate the functional roles of the most commonly detected alterations. Experimental Design: We studied a total of 249 tumor specimens from 208 patients. The specimens include 134 ER-positive (ER+/HER2−) and, as controls, 115 ER-negative (ER−) tumors. The ER+ samples consist of 58 primary breast cancers and 76 metastatic samples. All tumors were sequenced to high unique coverage using next-generation sequencing targeting the coding sequence of the estrogen receptor and an additional 182 cancer-related genes. Results: Recurring somatic mutations in codons 537 and 538 within the ligand-binding domain of ER were detected in ER+ metastatic disease. Overall, the frequency of these mutations was 12% [9/76; 95% confidence interval (CI), 6%–21%] in metastatic tumors and in a subgroup of patients who received an average of 7 lines of treatment the frequency was 20% (5/25; 95% CI, 7%–41%). These mutations were not detected in primary or treatment-naïve ER+ cancer or in any stage of ER− disease. Functional studies in cell line models demonstrate that these mutations render estrogen receptor constitutive activity and confer partial resistance to currently available endocrine treatments. Conclusions: In this study, we show evidence for the temporal selection of functional ESR1 mutations as potential drivers of endocrine resistance during the progression of ER+ breast cancer. Clin Cancer Res; 20(7); 1757–67. ©2014 AACR.

1 October 2017 in Cell Metabolism
Verified
Journal Article
Closed access
KLKyung-min Lee
Kyung-min Lee
JGJennifer M. Giltnane
Jennifer M. Giltnane
JBJustin M. Balko
Justin M. Balko
LSLuis J. Schwarz
Luis J. Schwarz
AGAngel L. Guerrero-Zotano
Angel L. Guerrero-Zotano
CACarlos L. Arteaga
Carlos L. Arteaga

8 February 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NBNeil E. Bhola
Neil E. Bhola
JBJustin M. Balko
Justin M. Balko
TDTeresa C. Dugger
Teresa C. Dugger
MKMaría Gabriela Kuba
María Gabriela Kuba
VSVioleta Sánchez
Violeta Sánchez
CACarlos L. Arteaga
Carlos L. Arteaga
After an initial response to chemotherapy, many patients with triple-negative breast cancer (TNBC) have recurrence of drug-resistant metastatic disease. Studies with TNBC cells suggest that chemotherapy-resistant populations of cancer stem-like cells (CSCs) with self-renewing and tumor-initiating capacities are responsible for these relapses. TGF-β has been shown to increase stem-like properties in human breast cancer cells. We analyzed RNA expression in matched pairs of primary breast cancer biopsies before and after chemotherapy. Biopsies after chemotherapy displayed increased RNA transcripts of genes associated with CSCs and TGF-β signaling. In TNBC cell lines and mouse xenografts, the chemotherapeutic drug paclitaxel increased autocrine TGF-β signaling and IL-8 expression and enriched for CSCs, as indicated by mammosphere formation and CSC markers. The TGF-β type I receptor kinase inhibitor LY2157299, a neutralizing TGF-β type II receptor antibody, and SMAD4 siRNA all blocked paclitaxel-induced IL8 transcription and CSC expansion. Moreover, treatment of TNBC xenografts with LY2157299 prevented reestablishment of tumors after paclitaxel treatment. These data suggest that chemotherapy-induced TGF-β signaling enhances tumor recurrence through IL-8–dependent expansion of CSCs and that TGF-β pathway inhibitors prevent the development of drug-resistant CSCs. These findings support testing a combination of TGF-β inhibitors and anticancer chemotherapy in patients with TNBC.